Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT03988309 · ClinicalTrials.gov registry record · NA

STRATA: Safe Testing of Risk for AsymptomaTic MicrohematuriA

A NA study of Urothelial Carcinoma and Hematuria, sponsored by Pacific Edge Limited.

Completed
Registry status
NA
Development phase
554
Enrollment target
12
Study locations

NCT03988309 is a NA study of Urothelial Carcinoma and Hematuria that has completed, run by Pacific Edge Limited. The registered enrollment target is 554 participants, above the 233-participant average among 85 other Urothelial Carcinoma trials with a reported enrollment target (138% higher). The trial reports 12 study locations across 10 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT03988309, a NA study of Urothelial Carcinoma and Hematuria, has completed, sponsored by Pacific Edge Limited.

COMPLETED
Registry status
NA
Development phase
554 participants
Enrollment target
12
Study locations

Study Summary

To evaluate the clinical utility associated with the integration of Cxbladder into the evaluation of subjects presenting with hematuria for evaluation of urothelial carcinoma (UC) without compromising detection of UC.

Interventions

  • DIAGNOSTIC_TEST Cxbladder

Study Locations (12)

Minnesota

  • Allina Health Cancer Institute - Minneapolis
  • University of Minnesota, Department of Urology - Minneapolis

Texas

  • UT Southwestern Medical Center - Dallas
  • UTHSA - Mays Cancer Center - San Antonio

California

  • Institute of Urology, USC Norris Comprehensive Cancer Center - Los Angeles

Florida

  • Avant Concierge Urology - Winter Garden

Illinois

  • Accellacare - Chicago

Pennsylvania

  • Division of urology, Penn State Milton S Hershey Medical Center - Hershey

South Carolina

  • Carolina Urologic Research Center - Myrtle Beach

Tennessee

  • Department of Urology,Vanderbilt University - Nashville

Trial Details

FieldValue
Enrollment Target 554 participants
Start Date 2019-09-11
Est. Completion 2024-07-24
Phase NA

Sponsor

Pacific Edge Limited

6 total trials

What the Registry Record Tells You About NCT03988309

The ClinicalTrials.gov registry entry for NCT03988309 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 554 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 233-participant average among 85 other Urothelial Carcinoma trials with a reported enrollment target (138% higher). The listed sponsor is Pacific Edge Limited, which has 6 total studies on file at ClinicalTrials.gov.

The record links to 2 conditions, with Urothelial Carcinoma appearing as the primary indexed condition, and to 1 intervention - of which Cxbladder is the first listed.

NCT03988309 reports 12 study locations spanning 10 distinct geographic areas - top geographies include Minnesota, Texas, California.

Frequently Asked Questions

What is clinical trial NCT03988309 about?

NCT03988309 is a clinical study titled "STRATA: Safe Testing of Risk for AsymptomaTic MicrohematuriA". To evaluate the clinical utility associated with the integration of Cxbladder into the evaluation of subjects presenting with hematuria for evaluation of urothelial carcinoma (UC) without compromising detection of UC.

What is the current status of trial NCT03988309?

This trial is currently completed. It is a NA study. The enrollment target is 554 participants. The study started on 2019-09-11. Estimated completion is 2024-07-24.

What conditions does trial NCT03988309 study?

This clinical trial studies the following conditions: Urothelial Carcinoma, Hematuria.

What interventions are being tested in trial NCT03988309?

The interventions under investigation include: Cxbladder (DIAGNOSTIC_TEST).

Who is sponsoring clinical trial NCT03988309?

This trial is sponsored by Pacific Edge Limited, which has 6 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT03988309 being conducted?

This trial has 12 study locations across California, Florida, Illinois, Minnesota, Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Urothelial Carcinoma

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.